Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Unfortunately this is the way with Itaconix. Bottom line - The company has failed to renegotiate with its largest customer.
This is a disaster and the share price for this year is screwed and I expect it to continue to fall lower.
Itaconix history seems to be that every time we think we are making progress we suffer a huge setback.
Itaconix has just lost its largest customer. Predicted Revenue for 2024 slashed by almost half!!!
This might be great for gross margin but it absolutely screws us for revenue.
I’m sorry but you can not paint a positive picture with this and the share price today and for the rest of 2024 will reflect this.
General market sentiment has been low going into tomorrow’s FOMC update. Tomorrow being seen as “local bottom for risk” and that market sentiment will swing up again.
That plus the Itaconix update in “early April” will likely see quick upward movement to 300p and hopefully beyond
Itx would certainly be a great fit for Unilever’s wider product ranges. The strength of the share price increase day after day, makes me wonder if a massive deal has been secured with Unilever.
12p in old money is where we should be, so 600p in today’s money. Thats what we have to look forward to :-) so continuing to hold fast.
Thanks AJP. This is John’s best interview to date. Really top drawer. Clear on progress to date, upcoming developments and expected progress. Sounds like they are still working to crack the super absorbent product but sounds like they’ve made massive progress on paints and leathers.
We they continue to grow at 40% then I calculate they will get to over $100 revenue in 2031.
Our current market cap is only $28m.
Serious re-rating must be coming.
Fair to say I am delighted to finally see the trading update and for it to be so positive. The biggest thing for me is that cash balance is still $10m which means the company is breaking even financially. Probably better than break even when you consider that it is investing heavily in future products and business. At last the turning point we have all been waiting for.
The timing of the one in December was bizarre and seemed to be a panic response to the continued fall in share price. The delay to 2023 FY results makes me sceptical. Any professional company should follow a regular schedule for updating its investors. Itaconix don’t. Without a doubt Itaconix is the most frustrating investment I have ever made.
i refuse to top up anymore in the absence of regular trading updates. we should have had fy 2023 weeks ago. i’m that ****ed off that i’m thinking about selling out of itaconix and regular readers here will know i have always been a strong supporter of the company. we are in a bull market but itaconix has not seen any share price growth. that is extremely worrying and there are 1001 other tech opportunities out there. let’s see if anything comes next week.
I do wish Itaconix would stick to a regular schedule for trading updates. You never know when the next one is coming which doesn’t inspire any confidence in the company. The TU to end of 2024 is now well overdue.
If anyone from the company is reading this please sort this out as it is very frustrating for investors.
Yes a VERY interesting appt when we are already flush with cash. This appointment feels all about driving the stock price up by making Itaconix more attractive to investors.
Could it be we are being lined up for a move onto the FTSE Smallcap Index?
I don’t usually have any problem buying on ii or Barclays
Where were you trying to buy?
Another great spot AJP. Thank you
Nice spot AJP
Fingers crossed we get an RNS next week
Last year the company released FY22 on 3rd February so should be soon
Good to see the share price rising again.
With the full year results just around the corner my main focus will be the gross margin as we already have a pretty accurate idea of revenue. I think the market will be looking for improving gross margins and if that occurs hopefully that will be a positive catalyst.
I have to admit I have considered selling some of my holding last year but I am glad that I didn’t. Having endured this long I know I would kick myself for selling out and then seeing the company fulfil its potential over coming months and years. With an enhanced management team in place, strategic links with Bemis and tons of cash to grow revenue it’s a perfect storm brewing IMO.
Having absorbed the video I have a few observations:
1. John Shaw and his team 100% read the comments on here, so we do have a voice. I am grateful that they have responded to many of the issues we have been talking about.
2. The development and progress of SAP and Bio-Asterix are clearly going to be key to the future success of ITX.
3. Looking forward to the new website and enhanced digital marketing (about time!)
4. The company is clearly a value play at 1.4 x revenue. 5. Interesting to hear JS discussing the acquisition question for the first time. If you notice, he didn’t rule it out. But hinted at SAP and bioasterix devpt being needed first to increase recognition of the powerful Itaconix platform.
The part below about analyst’s reducing Itaconix revenue expectations for 2024 and 2025 (which I had missed) explains why we saw the recent drop in share price.
Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw speaks to Thomas Warner from Proactive about how the company, which makes plant-based ingredients for consumer products, is positioned heading into the new year.
Shaw expresses optimism about the company's future and shared insights into its current status and strategies. Shaw highlights Itaconix's efforts to enhance its trading ability in the U.S., including overcoming challenges with share consolidations and brokerage protocols. He addresses concerns about the company's decreased share price, emphasising the intrinsic value created through significant advancements over the past two years.
Shaw points out the company's relatively low market valuation compared to its revenue growth and potential in the plant-based chemical sector. Shaw downplays the notion of Itaconix as an acquisition target, focusing instead on the company's commitment to expanding its technology platform, which has significant potential and a robust customer project pipeline. He also dismissed the idea of moving to another market, citing satisfaction with the current investor base.
Addressing analysts' reducing of Itaconix's revenue expectations for 2024 and 2025, Shaw clarified that this does not indicate a downturn in business. He attributes adjustments to the normalisation of inflated chemical prices and reassured that Itaconix's profitability and commercial milestones remain on track.
Looking ahead to 2024, Shaw expressed confidence in the company's strong position, driven by revenue growth, a solid customer pipeline, and new initiatives, including a focus on digital marketing and smaller accounts.
Interesting that John Shaw’s purchase yesterday was at $1.73 (about £1.37)